Physician profile
Michael Ryan Brison
NPI 1942756630
$546.18
in general payments reported to CMS, 2019-2025
12 companies · $37.58 in 2025
The $37.58 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $112 · 2024: $397 · 2025: $37.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $255.31 | 2023-2024 | |
| Exact Sciences Corporation | $68.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $34.83 | 2024 | |
| Astellas Pharma US INC | $28.13 | 2024 | Veozah |
| Ibsa Pharma INC. | $26.44 | 2024 | Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.91 | 2024 | |
| Glaxosmithkline, LLC. | $20.33 | 2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $19.86 | 2024 | Breztri |
| Phathom Pharmaceuticals, INC. | $19.38 | 2024 | Voquezna |
| Boston Scientific Corporation | $19.35 | 2025 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $17.05 | 2024 | Rexulti |
| Novo Nordisk INC | $14.22 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.